This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Roche Pharma (Schweiz) AG, as Chairman, Roche Pharma AG, as Chairman-Supervisory Board, Roche Diagnostics Deutschland GmbH, as Chairman-Supervisory Board, Roche Diabetes Care GmbH, as Chairman ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its chief markets in Asia. Roche is investing roughly 2.04 billion Chinese ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma (ZELA.CO), opens new tab in March. This therapy is currently undergoing mid-stage clinical trials.

So far in his second term, President Donald Trump has been trying to coerce international corporations to bolster their spending in the United States, including through his controversial tariffs.

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role. Anderson's departure was ...

The facility is intended to support Roche and Genentech’s portfolio of next-generation obesity medicines. In the pharmaceutical and diagnostics divisions, Roche and Genentech’s combined US footprint ...